Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group

British Journal of Cancer

Volumn 78, Issue 6, 1998, Pages 828-832

  De Wit, R ^a   Stoter, G ^a   Sleijfer, D Th ^b   Neijt, J P ^c   Ten Bokkel Huinink, W W ^d   De Prijck, L ^e   Collette, L ^e   Sylvester, R ^e  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e EORTC DATA CENTER   (Belgium)

Author keywords

Chemotherapy; Non seminatous germ cell cancer; Testicular cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; MESNA;

ARTICLE; BONE MARROW TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE FUNCTION; LEUKOPENIA; LUNG TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SEPSIS; TESTIS CANCER; THROMBOCYTOPENIA; UROGENITAL TRACT CANCER;

EID: 0031681280     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.587     Document Type: Article

References (19)

1. Agresti A (1990) Categorical Data Analysis. John Wiley and Sons: New York
2. Bajorin D, Katz A, Chan E, Geller N, Vogelzang N and Bosl GJ (1988) Comparison of criteria for assigning germ cell tumor patients to 'good risk' and 'poor risk' studies. J Clin Oncol 6: 786-792
3. Bokemeijer C, Harstrick A, Metzner B, Beyer J, Rüther, Berdel W, Casper J, Kührer I, Illinger HJ, Kempf B, Föller A, Holstein K, Derigs HG, Schinoll HJ, for the German Testicular Cancer Study Group (1996) Sequential high-dose VIP chemotherapy plus peripheral stem cell support for advance germ cell cancer. Ann Oncol 7 (suppl. 5): 55
4. Einhorn LH (1981) Testicular cancer as a model for a curable neoplasm: the Richard and Hilda Rosental Foundation Award lecture. Cancer Res 41: 3275-3280
5. Einhorn LH (1990) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8: 1777-1781
6. Einhorn LH and Williams SD (1980) Chemotherapy of disseminated testicular cancer. Cancer 46: 1339-1344
7. International Germ Cell Cancer Collaborative Group (1996) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594-603
8. Kalbfleish JD and Prentice RL (1980) The Statistical Analysis of Failure Time Data. John Wiley and Sons: New York
9. Kaye SB, Mead GM, Fossa S, Cullen M, Wit de R, Bodrogi I, Groeningen van C, Sylvester R, Colette L, Stenning S, Prijek de L, Lallemand E, Mulder de P (1997) Intensive induction sequential chemotherapy (BOP/VIP-B)compared to standard treatment (BEP) for 'poor programs' metastatic non-seminomatous germ cell tumour: a randomised MRC/EORTC study. J Clin Oncol 16: 692-701
10. Lehman EL (1975) Nonparametrics: Statistical Methods Based on Ranks. Holden-Day: San Francisco, p 81
11. Loehrer PJ, Lauer R, Roth BJ, Williams SD, Kalasinski LA and Einhorn LH (1988) Salvage therapy in recurrent germ cell cancer: ifofamide and cisplatin plus either vinblastine or etoposide. Ann Int Med 75: 540-546
12. Loehrer PJ, Einhorn LH, Elson P, Williams SD, Havlin K, Vogelzang NJ, Crawford ED, Trump DL, for the Eastern Cooperative Oncology Group, Madison, WI. USA; the Southwest Oncology Group, San Antonio, TX, USA; and the Cancer and Leukemia Group B, Boston, MA, USA (1993) Phase III study of cisplatin plus etoposide with either bleomycine or ifosfamide in advanced stage germ cell tumors: an intergroup trial. Proc Am Soc Clin Oncol 12: 261
13. McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V and Motzer RJ (1997) Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15: 2559-2563
14. Mead GM, Stenning SP, Parkinson MC, Horwich A, Fossa SD, Wilkinson PM, Kaye SB, Newlands ES, Cock PA for the Medical Research Council Testicular Tumour Working Party (1992) The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumours. J Clin Oncol 10: 85-94
15. Motzer RJ, Cooper K, Geller NL, Bajurin DF, Dmitiovsky E, Herr H, Morse M, Fair W, Sogani P and Bosl GJ (1990) The role of ifosfamide + cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 66: 2476-2481
16. Munshi NC, Loehrer PJ, Roth BJ et al (1990) Vinblastine, ifosfamide and cisplatin (VIP) as second line chemotherapy in metastatic germ cell tumors (GCT). Proc Am Soc Clin Oncol 9: 134
17. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH and Loehrer PJ (1998) Randomized comparison of cisplatin and etoposide and either Bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumours: an Eastern Cooperative Oncology Group, Southwest (Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 16: 1287-1293
18. Stoter G, Sylvester R, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, Jones WG, van Oosteron AT, Vendrik CPJ, Spaander P and de Pauw M (1987) Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from an EORTC multiinstitutional phase III study. Cancer Res 47: 2714-2718
19. Stoter G, Sleyfer DT, Schornagel JH, ten Bokkel Huinink WW, Vermeijlen K, Sylvester R on behalf of the EORTC Genito-Urinary Group (1993) BEP versus VIP in intermediate risk patients with disseminated non-seminomatous testicular cancer. Proc Am Soc Clin Oncol 12: 232